Ophthalmic preparation containing menthyl ester of indomethacin

Abstract

There is provided an ophthalmic pharmaceutical preparation comprising menthyl ester of indomethacin as an active ingredient. Also provided are different possible formulations of the ophthalmic preparation, and different methods of treating ophthalmic irritation using the ophthalmic preparation.

1 - 23 . (canceled) 
     
     
         24 . A pharmaceutical composition for parenteral administration, comprising:
 i. a menthyl ester of indomethacin and   ii. a first lipid component;   wherein the composition is a colloidal delivery system selected from group consisting of: a suspension, a nanoparticle, a micellar solution, and an emulsion.   
     
     
         25 . The pharmaceutical composition of  claim 24 , wherein the concentration of menthyl ester of indomethacin is 0.05 to 5.0% weight-by-weight. 
     
     
         26 . The pharmaceutical composition of  claim 24 , wherein the lipid component is selected from the group consisting of: a first oil, a first surfactant, and a combination of the foregoing. 
     
     
         27 . The pharmaceutical composition of  claim 26 , wherein the first oil is selected from the group consisting of: a medium chain triglyceride, tocopherol acetate, tocopherol, acetylated glycerides, caster oil, and a combination of the foregoing. 
     
     
         28 . The pharmaceutical composition of  claim 26 , wherein the first surfactant is selected from the group consisting of: solutol-HS-15, lecithin, tyloxapol, polyethoxylated castor oil, α-tocopherol-PEG-1000-succinate, poloxamer 188, polysorbate-80, and a combination of the foregoing. 
     
     
         29 . The pharmaceutical composition of  claim 24 , further comprising a co-solvent. 
     
     
         30 . The pharmaceutical composition of  claim 29 , wherein the co-solvent is selected from the group consisting of: glycerin, ethanol, chlorobutanol, and combinations of the foregoing. 
     
     
         31 . The pharmaceutical composition of claim  1 , wherein the emulsion particle or nanoparticle size range is from 15 to 500 nm in diameter. 
     
     
         32 . A method of treating pain or inflammation in a patient in need thereof, comprising:
 i. parenterally administering the pharmaceutical composition comprising:
 a. a menthyl ester of indomethacin and 
 b. a first lipid component; 
   wherein the composition is a colloidal delivery system selected from group consisting of: a suspension, a micellar solution, and an emulsion.   
     
     
         33 . The method of  claim 32 , wherein the concentration of menthyl ester of indomethacin is 0.05 to 5.0% weight-by-weight. 
     
     
         34 . The method of  claim 32 , wherein the lipid component is selected from the group consisting of: a first oil, a first surfactant, and a combination of the foregoing. 
     
     
         35 . The method of  claim 34 , wherein the first oil is selected from the group consisting of: a medium chain triglyceride, tocopherol acetate, tocopherol, acetylated glycerides, caster oil, and a combination of the foregoing. 
     
     
         36 . The method of  claim 34 , wherein the first surfactant is selected from the group consisting of: solutol-HS-15, lecithin, tyloxapol, polyethoxylated castor oil, α-tocopherol-PEG-1000-succinate, poloxamer 188, polysorbate-80, and a combination of the foregoing. 
     
     
         37 . The method of  claim 32 , wherein the pharmaceutical composition further comprises a co-solvent. 
     
     
         38 . The method of  claim 37 , wherein the co-solvent is selected from the group consisting of: glycerin, ethanol, chlorobutanol, and combinations of the foregoing.